Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00002362
- Locations
- 🇺🇸
Northstar Med Clinic, Chicago, Illinois, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
🇺🇸Univ of Texas / Med School at Houston, Houston, Texas, United States
Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00002220
- Locations
- 🇺🇸
Hawaii AIDS Clinical Trial Unit, Honolulu, Hawaii, United States
🇺🇸LAC / USC Med Ctr / Infectious Diseases, Los Angeles, California, United States
🇺🇸Med Ctr of Delaware, Wilmington, Delaware, United States
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 100
- Registration Number
- NCT00002230
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
A Study of Efavirenz in Combination With Stavudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 60
- Registration Number
- NCT00002225
- Locations
- 🇺🇸
Univ of Rochester Med Ctr, Rochester, New York, United States
🇺🇸AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸North Shore AIDS Hosp / Division of Infectious Disease, Manhassett, New York, United States
A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT00002448
- Locations
- 🇺🇸
Palo Alto Veterans Affairs Health Care System, Palo Alto, California, United States
🇺🇸UCLA Care Ctr, Los Angeles, California, United States
🇺🇸Robert Wood Johnson Med School/UMDNJ, New Brunswick, New Jersey, United States
Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-02
- Target Recruit Count
- 76
- Registration Number
- NCT00016601
- Locations
- 🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Indiana Univ Hosp, Indianapolis, Indiana, United States
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 1125
- Registration Number
- NCT00013520
- Locations
- 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 300
- Registration Number
- NCT00000918
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 444
- Registration Number
- NCT00000903
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic, San Rafael, California, United States
A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 800
- Registration Number
- NCT00000914
- Locations
- 🇺🇸
North Jersey Community Research Initiative, Newark, New Jersey, United States
🇺🇸Community Consortium / UCSF, San Francisco, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.